◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › IQV

IQVIA Holdings Inc (IQV) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Life Sciences Tools & Services · DATA UPDATED 2026-07-15

IQVIA Holdings Inc (IQV) operates in the Life Sciences Tools & Services industry and is headquartered in Durham, United States with about 93,000 employees. Its market capitalization is roughly $35 billion. In the fiscal year ended 2025-12-31, IQV reported $16.3B in revenue and $1.4B in net income.

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.

Interactive charts & full statements → Open the IQV valuation workbench →

IQV Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Revenue	$16.6B	$16.3B	$15.4B	$15.0B	$14.4B	$13.9B	$11.4B	$11.1B	$10.4B	$9.7B	$6.8B	$5.7B	$5.5B	$5.1B	$4.9B	$4.3B	$3.9B
Gross Profit	$4.3B	$4.3B	$5.4B	$5.2B	$5.0B	$4.6B	$3.9B	$3.8B	$3.7B	$3.4B	$2.1B	$1.6B	$1.5B	$1.3B	$1.2B	$1.1B	$1.1B
Gross Margin %	26.1%	26.3%	34.9%	35.0%	34.9%	33.5%	34.0%	34.2%	35.2%	35.0%	30.3%	28.3%	27.5%	26.2%	25.3%	26.4%	28.5%
Operating Income (EBIT)	$2.3B	$2.3B	$2.2B	$2.0B	$1.8B	$1.4B	$731M	$777M	$741M	$719M	$642M	$647M	$590M	$462M	$396M	$345M	$395M
Operating Margin %	13.9%	14.0%	14.3%	13.2%	12.5%	10.0%	6.4%	7.0%	7.1%	7.4%	9.4%	11.3%	10.8%	9.1%	8.2%	8.0%	10.1%
Net Income	$1.4B	$1.4B	$1.4B	$1.4B	$1.1B	$966M	$279M	$191M	$259M	$1.3B	$115M	$387M	$356M	$227M	$178M	$242M	$161M
Net Margin %	8.3%	8.3%	8.9%	9.1%	7.6%	7.0%	2.5%	1.7%	2.5%	13.5%	1.7%	6.8%	6.5%	4.4%	3.6%	5.6%	4.1%
EBITDA	$3.5B	$3.5B	$3.5B	$3.3B	$2.9B	$2.8B	$2.1B	$2.0B	$1.9B	$1.7B	$849M	$768M	$723M	$554M	$500M	$386M	$467M
Earnings Per Share (EPS)	$8.07	$7.84	$7.49	$7.29	$5.72	$4.95	$1.43	$0.96	$1.24	$5.88	$0.76	$3.08	$2.72	$1.77	$1.39	$1.90	$1.26
Shares Outstanding (M)	170M	174M	183M	186M	191M	195M	195M	200M	208M	223M	152M	126M	131M	128M	128M	128M	128M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IQV Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$4.2B	$4.4B	$4.1B	$4.0B	$3.8B	$4.0B	$3.9B	$3.8B
Gross Profit	$1.4B	$292M	$1.4B	$1.3B	$1.3B	$1.4B	$1.4B	$1.1B
Gross Margin %	32.6%	6.7%	33.5%	32.9%	33.9%	34.8%	35.4%	27.7%
Operating Income (EBIT)	$514M	$732M	$553M	$506M	$496M	$626M	$550M	$548M
Operating Margin %	12.4%	16.8%	13.5%	12.6%	13.0%	15.8%	14.1%	14.4%
Net Income	$274M	$514M	$331M	$266M	$249M	$437M	$285M	$363M
Net Margin %	6.6%	11.8%	8.1%	6.6%	6.5%	11.0%	7.3%	9.5%
EBITDA	$808M	$1.0B	$883M	$781M	$753M	$1.0B	$797M	$883M
Earnings Per Share (EPS)	$1.61	$2.99	$1.93	$1.54	$1.40	$2.42	$1.55	$1.97
Shares Outstanding (M)	170M	172M	172M	173M	177M	181M	184M	184M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IQV Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Cash from Operations (CFO)	$2.7B	$2.7B	$2.7B	$2.1B	$2.3B	$2.9B	$2.0B	$1.4B	$1.3B	$970M	$860M	$476M	$432M	$397M	$336M	$161M	$378M
Capital Expenditures (CapEx)	$745M	$603M	$602M	$649M	$674M	$640M	$616M	$582M	$459M	$369M	$164M	$78M	$83M	$92M	$71M	$76M	$80M
Free Cash Flow (FCF)	$2.0B	$2.1B	$2.1B	$1.5B	$1.6B	$2.3B	$1.3B	$835M	$795M	$601M	$696M	$397M	$349M	$305M	$264M	$85M	$298M
FCF Margin %	11.8%	12.6%	13.7%	10.0%	11.0%	16.6%	11.8%	7.5%	7.6%	6.2%	10.2%	6.9%	6.4%	6.0%	5.4%	2.0%	7.6%
Dividends Paid	—	—	—	—	—	$59M	$44M	$11M	$4.1B	$7.2B	$638M	$2.2B	$425M	$2.1B	$568M	$288M	$67M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IQV Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$618M	$735M	$908M	$443M	$568M	$885M	$721M	$588M
Capital Expenditures (CapEx)	$127M	$174M	$293M	$151M	$142M	$164M	$150M	$143M
Free Cash Flow (FCF)	$491M	$561M	$615M	$292M	$426M	$721M	$571M	$445M
FCF Margin %	11.8%	12.9%	15.0%	7.3%	11.1%	18.2%	14.7%	11.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IQV Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$29.7B	$29.9B	$26.9B	$26.7B	$25.3B	$24.7B	$24.6B	$23.3B	$22.5B	$22.7B	$21.2B	$3.9B	$3.3B	$3.1B	$2.5B	$2.3B
Cash & Cash Equivalents	$1.9B	$2.0B	$1.7B	$1.4B	$1.2B	$1.4B	$1.8B	$837M	$891M	$959M	$1.2B	$977M	$867M	$778M	$568M	$516M
Total Liabilities	$23.3B	$23.3B	$20.8B	$20.6B	$19.6B	$18.6B	$18.3B	$17.0B	$15.6B	$14.4B	$12.3B	$4.3B	$4.0B	$3.7B	$3.9B	$3.3B
Total Debt (Short + Long-Term)	$15.8B	$15.7B	$14.0B	$13.7B	$12.7B	$12.1B	$12.5B	$11.6B	$11.0B	$10.2B	$7.2B	$2.5B	$2.3B	$2.0B	$2.4B	$2.0B
Total Shareholders' Equity	$6.2B	$6.5B	$6.1B	$6.1B	$5.8B	$6.0B	$6.0B	$6.0B	$6.7B	$8.1B	$8.6B	($336M)	($704M)	($667M)	($1.4B)	($970M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IQV viewer.

Other Companies in Life Sciences Tools & Services

TMO · Thermo Fisher Scientific — $211 billion
DHR · Danaher Corporation — $135 billion
A · Agilent Technologies — $39 billion
WAT · Waters Corporation — $37 billion
MTD · Mettler Toledo — $27 billion
TECH · Bio-Techne — $11 billion
CRL · Charles River Laboratories — $11 billion

← IQST All stocks IR →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.